Jan R R Lewis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jan R R Lewis has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ian Kerridge
The University of Sydney, Sydney, Australia
4 shared publications - Wendy Lipworth
Department of Philosophy, Macquarie University, Sydney, NSW, Australia
4 shared publications - Evan Doran
Centre for Clinical Epidemiology and Biostatistics, The University of Newcastle, Callaghan, NSW, Australia
1 shared publication - Richard Osborne Day
St Vincent’s Clinical Campus, School of Medicine, St Vincent’s Hospital, University of New South Wales, Darlinghurst, Australia
1 shared publication
Latest Publications
- 1 December 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (34) , 4112-4117
Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology
Personalized medicines hold promise for many diseases. However, demonstrating the clinical efficacy and cost effectiveness of these medicines can be difficult. It is essential that decision-making processes for funding new medicines, including personalized medicines, are both robust and fit for purpose. We will argue that randomized trials of personalized medicines should be routinely supplemented with other research methods, such as observational research and single-arm studies, and that managed-entry funding programs, such as coverage with evidence development, may offer a means of providing early access to technologies where there is uncertainty about efficacy, safety, and cost effectiveness. These programs, however, raise a number of practical and ethical challenges that need to be worked through and resolved.
- 1 December 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (34) , 4112-4117
Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology
Personalized medicines hold promise for many diseases. However, demonstrating the clinical efficacy and cost effectiveness of these medicines can be difficult. It is essential that decision-making processes for funding new medicines, including personalized medicines, are both robust and fit for purpose. We will argue that randomized trials of personalized medicines should be routinely supplemented with other research methods, such as observational research and single-arm studies, and that managed-entry funding programs, such as coverage with evidence development, may offer a means of providing early access to technologies where there is uncertainty about efficacy, safety, and cost effectiveness. These programs, however, raise a number of practical and ethical challenges that need to be worked through and resolved.
- 8 September 2014
- Published by Wiley in Internal Medicine Journal
- Vol. 44 (9) , 841-845
Dilemmas in the compassionate supply of investigational cancer drugs
In Australia, patients who want to access medicines that are not yet approved have only two options: to enrol in a clinical trial if they are eligible, or obtain their medicine through ‘compassionate supply’, which is provided at the discretion of the manufacturer. In this article, we explore ethical issues associated with the provision of oncology medicines that are still in development, either prior to regulatory approval or government reimbursement.
- 8 September 2014
- Published by Wiley in Internal Medicine Journal
- Vol. 44 (9) , 841-845
Dilemmas in the compassionate supply of investigational cancer drugs
In Australia, patients who want to access medicines that are not yet approved have only two options: to enrol in a clinical trial if they are eligible, or obtain their medicine through ‘compassionate supply’, which is provided at the discretion of the manufacturer. In this article, we explore ethical issues associated with the provision of oncology medicines that are still in development, either prior to regulatory approval or government reimbursement.
- Open Access
- 27 March 2014
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 4 (2) , 137-146
Ethics, Evidence and Economics in the Pursuit of “Personalized Medicine”
Despite enthusiastic advocacy for what personalized medicine might be able to deliver and major investments into the development of this, there remain disappointingly few examples of personalized medicine in routine clinical practice today, particularly in high areas of unmet need such as cancer. We believe that this is because personalized medicine challenges the moral, economic and epistemological foundations of medicine. In this article, we briefly describe the scientific premises underpinning personalized medicine, contrast these with traditional paradigms of drug development, and then consider the ethical, economic and epistemological implications of this approach to medicine.
- 27 March 2014
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 4 (2) , 137-146
Open AccessEthics, Evidence and Economics in the Pursuit of “Personalized Medicine”
Despite enthusiastic advocacy for what personalized medicine might be able to deliver and major investments into the development of this, there remain disappointingly few examples of personalized medicine in routine clinical practice today, particularly in high areas of unmet need such as cancer. We believe that this is because personalized medicine challenges the moral, economic and epistemological foundations of medicine. In this article, we briefly describe the scientific premises underpinning personalized medicine, contrast these with traditional paradigms of drug development, and then consider the ethical, economic and epistemological implications of this approach to medicine.
- 7 October 2013
- Published by AMPCo in Medical Journal of Australia
- Vol. 199 (7) , 471-473
The economic evaluation of personalised oncology medicines: ethical challenges
Does the current evidence-based medicine model for assessing the clinical and cost-effectiveness of personalised therapies need revision?
- 7 October 2013
- Published by AMPCo in Medical Journal of Australia
- Vol. 199 (7) , 471-473
The economic evaluation of personalised oncology medicines: ethical challenges
Does the current evidence-based medicine model for assessing the clinical and cost-effectiveness of personalised therapies need revision?